Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

NCT02494583 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

763

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Cisplatin
DRUG: 5-FU
DRUG: Capecitabine
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC